Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Status unconfirmed · Phase 2

Conditions studied: HIV Infections

In brief

The purpose of this study is to see if it is safe to give indinavir (IDV) and ritonavir (RTV) in combination with stavudine (d4T) and lamivudine (3TC) to HIV-positive patients who have never received anti-HIV therapy. This study will look at the effectiveness of this drug combination and side effects.

Key facts

Study ID

NCT00002451

Run by

Merck Sharp & Dohme LLC

People needed

8

Last updated by the study team

2005-06-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients may be eligible for this study if they:
• Are HIV-positive.
• Are at least 18 years old.
• Have a viral load of 5,000 copies/ml or greater.
• Have a CD4 count of at least 50 cells/mm3.

You may not qualify if…

• Patients will not be eligible for this study if they:
• Have taken any antiretroviral (anti-HIV) agent.
• Are pregnant.

Where it is running

• Univ of Miami School of Medicine — Miami, Florida, United States
• Albany Med College — Albany, New York, United States
• SUNY at Stony Brook / Division of Infectious Diseases — Stony Brook, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.